Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
Status:
Terminated
Trial end date:
2016-06-14
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies romidepsin in treating patients with graft-versus-host
disease (GVHD) that has not responded to treatment with steroids. Romidepsin may be an
effective treatment for graft-versus-host disease caused by a bone marrow or stem cell
transplant.
Phase:
N/A
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey